Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NMRA |
---|---|---|
09:32 ET | 4190 | 9.7201 |
09:34 ET | 200 | 9.67 |
09:36 ET | 1100 | 9.7812 |
09:38 ET | 200 | 9.79 |
09:39 ET | 2155 | 9.76 |
09:41 ET | 2333 | 9.76 |
09:43 ET | 800 | 9.89 |
09:48 ET | 300 | 9.89 |
09:50 ET | 200 | 9.86 |
09:52 ET | 2702 | 9.84 |
09:54 ET | 100 | 9.8 |
09:56 ET | 5671 | 9.98 |
09:57 ET | 200 | 9.96 |
09:59 ET | 2866 | 9.9 |
10:01 ET | 3555 | 10 |
10:03 ET | 2993 | 10 |
10:06 ET | 900 | 10 |
10:08 ET | 1700 | 9.98 |
10:10 ET | 3917 | 9.92 |
10:12 ET | 1100 | 9.91 |
10:14 ET | 3237 | 9.96 |
10:15 ET | 1959 | 9.94 |
10:17 ET | 1505 | 9.9 |
10:21 ET | 2785 | 9.93 |
10:24 ET | 1100 | 9.9 |
10:26 ET | 1755 | 9.87 |
10:28 ET | 1101 | 9.86 |
10:30 ET | 1678 | 9.88 |
10:32 ET | 100 | 9.89 |
10:33 ET | 300 | 9.91 |
10:37 ET | 960 | 9.92 |
10:39 ET | 2514 | 9.89 |
10:44 ET | 3522 | 9.85 |
10:46 ET | 200 | 9.84 |
10:48 ET | 100 | 9.84 |
10:50 ET | 300 | 9.83 |
10:51 ET | 1300 | 9.835 |
10:53 ET | 3362 | 9.85 |
10:55 ET | 400 | 9.85 |
10:57 ET | 2550 | 9.84 |
11:00 ET | 200 | 9.84 |
11:02 ET | 4336 | 9.85 |
11:04 ET | 600 | 9.85 |
11:06 ET | 100 | 9.85 |
11:08 ET | 3463 | 9.825 |
11:11 ET | 3029 | 9.85 |
11:13 ET | 300 | 9.8492 |
11:15 ET | 796 | 9.85 |
11:18 ET | 550 | 9.85 |
11:20 ET | 2400 | 9.84 |
11:22 ET | 1529 | 9.83 |
11:24 ET | 200 | 9.82 |
11:26 ET | 500 | 9.82 |
11:27 ET | 2696 | 9.85 |
11:31 ET | 700 | 9.9 |
11:38 ET | 100 | 9.905 |
11:40 ET | 200 | 9.905 |
11:42 ET | 100 | 9.905 |
11:44 ET | 200 | 9.91 |
11:45 ET | 5776 | 9.87 |
11:47 ET | 3191 | 9.92 |
11:49 ET | 850 | 9.925 |
11:54 ET | 1166 | 9.9325 |
11:56 ET | 631 | 9.91 |
11:58 ET | 871 | 9.91 |
12:00 ET | 2625 | 9.895 |
12:02 ET | 1100 | 9.88 |
12:03 ET | 1800 | 9.87 |
12:05 ET | 200 | 9.85 |
12:07 ET | 500 | 9.85 |
12:09 ET | 800 | 9.85 |
12:12 ET | 5072 | 9.875 |
12:14 ET | 838 | 9.875 |
12:16 ET | 4665 | 9.86 |
12:18 ET | 155 | 9.86 |
12:20 ET | 300 | 9.84 |
12:21 ET | 600 | 9.84 |
12:23 ET | 906 | 9.84 |
12:25 ET | 900 | 9.84 |
12:27 ET | 200 | 9.84 |
12:30 ET | 400 | 9.84 |
12:32 ET | 350 | 9.85 |
12:34 ET | 200 | 9.84 |
12:36 ET | 6155 | 9.77 |
12:38 ET | 800 | 9.78 |
12:39 ET | 200 | 9.76 |
12:41 ET | 300 | 9.76 |
12:43 ET | 800 | 9.76 |
12:45 ET | 4836 | 9.81 |
12:48 ET | 316 | 9.81 |
12:50 ET | 100 | 9.81 |
12:52 ET | 3647 | 9.78 |
12:54 ET | 250 | 9.76 |
12:56 ET | 200 | 9.76 |
12:57 ET | 1652 | 9.76 |
12:59 ET | 3273 | 9.7504 |
01:01 ET | 1913 | 9.74 |
01:03 ET | 3720 | 9.75 |
01:06 ET | 5675 | 9.78 |
01:08 ET | 100 | 9.76 |
01:10 ET | 100 | 9.76 |
01:12 ET | 100 | 9.755 |
01:14 ET | 1742 | 9.775 |
01:17 ET | 300 | 9.76 |
01:19 ET | 400 | 9.775 |
01:21 ET | 1517 | 9.75 |
01:24 ET | 400 | 9.755 |
01:26 ET | 600 | 9.755 |
01:28 ET | 13597 | 9.69 |
01:30 ET | 2210 | 9.68 |
01:32 ET | 6041 | 9.67 |
01:33 ET | 269 | 9.6865 |
01:35 ET | 1200 | 9.66 |
01:37 ET | 300 | 9.63 |
01:39 ET | 1321 | 9.625 |
01:42 ET | 414 | 9.62 |
01:44 ET | 465 | 9.6 |
01:46 ET | 1991 | 9.64 |
01:48 ET | 245 | 9.635 |
01:50 ET | 604 | 9.63 |
01:51 ET | 1800 | 9.62 |
01:53 ET | 100 | 9.625 |
01:55 ET | 4222 | 9.61 |
02:00 ET | 100 | 9.6 |
02:02 ET | 100 | 9.61 |
02:04 ET | 1054 | 9.62 |
02:09 ET | 700 | 9.61 |
02:11 ET | 3781 | 9.67 |
02:13 ET | 400 | 9.6901 |
02:15 ET | 300 | 9.69 |
02:18 ET | 7135 | 9.695 |
02:20 ET | 2486 | 9.68 |
02:22 ET | 303 | 9.68 |
02:24 ET | 331 | 9.67 |
02:26 ET | 100 | 9.67 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Neumora Therapeutics Inc | 1.6B | -6.3x | --- |
Keros Therapeutics Inc | 1.6B | -8.3x | --- |
Akero Therapeutics Inc | 1.6B | -7.0x | --- |
Kura Oncology Inc | 1.6B | -9.5x | --- |
Morphic Holding Inc | 1.6B | -9.1x | --- |
Soleno Therapeutics Inc | 1.5B | -15.0x | --- |
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 159.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.55 |
Book Value | $2.95 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.